Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinaseactivated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects

Drugs in R and D

Volumn 12, Issue 3, 2012, Pages 141-163

  Namour, Florence ^a   Vanhoutte, Frdric P ^b   Beetens, Johan ^b   Blockhuys, Stan ^b   De Weer, Marc ^b   Wigerinck, Piet ^b  

^a Galapagos SASU   (France)

^b GALAPAGOS NV   (Belgium)

Author keywords

Drug interactions; MAP kinase activated kinase 5 inhibitors; Methotrexate; Pharmacokinetic pharmacodynamic relationships; Pharmacokinetics.

Indexed keywords

GLPG 0259; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; METHOTREXATE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84865835096     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11633120-000000000-00000     Document Type: Article

References (20)

1. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 2: 473-88
2. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-74
3. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61
4. Van Vollenhoven R. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatology 2009; 5: 531-41
5. McInnes I, O'Dell Jr. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1898-906
6. Yazici Y, Regens AL. Promising new treatments for rheumatoid arthritis: the kinase inhibitors. Bull NYU Hosp Jt Dis 2011; 69: 233-7
7. Westhovens R, De Keyser F, Rekalov D, et al. A twelveweek exploratory phase II trial of GLPG0259 versus placebo in patients with active rheumatoid arthritis and inadequate response to methotrexate [abstract no. 2237]. Arthritis Rheum 2011; 63 Suppl. 10; 2237 [online]. Available from URL: http://onlinelibrary.wiley.com/doi/10. 1002/art.33310/pdf [Accessed 2012 Jul 31]
8. Center for Drug Evaluation and Research [CDER], Food and Drug Administration, US Department of Health and Human Services. Guidance for industry: food-effect bioavailability and fed bioequivalence studies. Rockville (MD): CDER: 2002 Dec [online]. Available from URL: http://www.fda.gov/downloads/ regulatoryinformation/guid ances/ucm126833.pdf [Accessed 2012 Jul 31]
9. Center for Drug Evaluation and Research [CDER], Food and Drug Administration, US Department of Health and Human Services. Guidance for industry: population pharmacokinetics. Rockville (MD): CDER: 1999 Feb [online]. Available fromURL: http://www.fda.gov/downloads/Science Research/SpecialTopics/ WomensHealthResearch/UCM133 184.pdf [Accessed 2012 Jul 31]
10. Committee for Medicinal Products for HumanUse, European Medicines Agency [EMEA]. Guideline on reporting the results of population pharmacokinetic analyses. London: EMEA, 2007 Jun 21 [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/ewp/18599006enfin.pdf [Accessed 2012 Jul 31]
11. Beal SL, Sheiner LB, Boeckmann AJ, et al., editors. NONMEM users guides. Ellicott City (MD): Icon Development Solutions, 1989-2009
12. R Development Core Team. The R project for statistical computing [online]. Available from URL: http://www.r-project.org/[Accessed 2012 Jul 31]
13. WinPOPT Development Team. WinPOPT [online]. Available from URL: http://www.winpopt.com/index.htm [Accessed 2012 Jul 31]
14. Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 1995; 22: 2072-7
15. Bannwarth B, Pe'hourcq F, Schaeverbeke T, et al. Clinical pharmacokinetics of low-dose methotrexate in rheumatoid patients. Clin Pharmacokinet 1996 Mar; 30: 194-210
16. Jonsson EN, Wade JR, Karlsson MO. Nonlinearity detection: advantages of nonlinear mixed-effects modeling. AAPS PharmSci 2000; 2: E32
17. Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 1978; 3: 1-13
18. Smolen JS, Landewé R, Breedveld FC, et al. Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75
19. Mahmood I. Application of allometric principles for the predictions of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 2007; 59: 1177-92
20. Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995 Mar; 12: 413-20